Tumor treating fields: A new frontier in cancer therapy

Annals of the New York Academy of Sciences

Volumn 1291, Issue 1, 2013, Pages 86-95

  Davies, Angela M ^a   Weinberg, Uri ^a   Palti, Yoram ^a  

^a Novocure GmbH   (Israel)

Author keywords

Cancer treatment; Central nervous system cancer; Glioblastoma; NovoTTF 100A System; TTFields therapy; Tumor treatment fields

Indexed keywords

CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ERLOTINIB; GEMCITABINE; PACLITAXEL; PEMETREXED; TEMOZOLOMIDE;

ANAPHASE; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER THERAPY; ELECTRIC FIELD; GLIOBLASTOMA; MEMBRANE DEPOLARIZATION; METAPHASE; MITOSIS SPINDLE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; RADIATION DOSE; RECURRENT CANCER; TUMOR TREATING FIELD;

EID: 84880512034     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12112     Document Type: Article

References (41)

1. Kirson, E.D. et al. 2004. Disruption of cancer cell replication by alternating electric fields. Cancer Res. 64: 3288-3295.
2. Kirson, E.D. et al. 2009. Chemotherapeutic treatment efficacy and sensitivity are increased by adjuvant alternating electric fields (TTFields). BMC Med. Phys. 9: 1.
3. Schneiderman, R.S. et al. 2010. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters. BMC Cancer 10: 229.
4. Kirson, E.D. et al. 2009. Alternating electric fields (TTFields) inhibit metastatic spread of solid tumors to the lungs. Clin. Exp. Metast. 26: 633-640.
5. Stupp, R. et al. 2012. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur. J. Cancer 48: 2192-2202.
6. Salzberg, M. et al. 2008. A pilot study with very low-intensity, intermediate-frequency electric fields in patients with locally advanced and/or metastatic solid tumors. Onkologie 31: 362-365.
7. Pless, M. et al. 2010. A phase II study of tumor treating fields (TTFields) in combination with pemetrexed for advanced non small cell lung cancer (NSCLC). Eur. Soc. Med. Oncol. 21(Suppl 8): viii122-viii161.
8. Weinberg, U. et al. 2010. An open label pilot study of tumor treating fields (TTFields) in combination with pemetrexed for advanced non-small cell lung cancer (NSCLC). In ERS Annual Congress. Abstract 363.
9. Palti, Y. 1962. Stimulation of muscles and nerves by means of externally applied electrodes. Bull. Res. Counc. Isr. Sect. E Exp. Med. 10: 54-56.
10. Palti, Y. 1966. Stimulation of internal organs by means of externally applied electrodes. J. Appl. Physiol. 21: 1619-1623.
11. Rotshenker, S. & Y. Palti. 1973. Changes in fraction of current penetrating an axon as a function of duration of stimulating pulse. J. Theor. Biol. 41: 401-407.
12. Bostock, H. 1983. The strength-duration relationship for excitation of myelinated nerve: computed dependence on membrane parameters. J. Physiol. 341: 59-74.
13. Ehrenberg, B. et al. 1987. Membrane potential induced by external electric field pulses can be followed with a potentiometric dye. Biophys. J. 51: 833-837.
14. Siems, L.L., A.J. Kosman & S.L. Osborne. 1948. A comparative study of short wave and microwave diathermy on blood flow; the role of the somatic and sympathetic nerves in the vascular response to deep tissue heating. Arch. Phys. Med. Rehabil. 29: 759-764.
15. Yang, W.J. & J.H. Wang. 1979. Shortwave and microwave diathermy for deep-tissue heating. Med. Biol. Eng. Comput. 17: 518-524.
16. Cheng, Y.C. et al. 1998. Calculated RF electric field and temperature distributions in RF thermal ablation: comparison with gel experiments and liver imaging. J. Magnet. Reson. Imaging 8: 70-76.
17. Rossi, S. et al. 1996. Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer. Am. J. Roentgenol. 167: 759-768.
18. Sowers, A.E. 1984. Characterization of electric field-induced fusion in erythrocyte ghost membranes. J, Cell Biol. 99: 1989-1996.
19. Takashima, S. & H.P. Schwan. 1985. Alignment of microscopic particles in electric fields and its biological implications. Biophys. J. 47: 513-518.
20. Zimmermann, U., J. Vienken & G. Pilwat. 1981. Rotation of cells in an alternating electric field: the occurrence of a resonance frequency. Z. Naturforsch. 36: 173-177.
21. Holzapfel, C., J. Vienken & U. Zimmermann. 1982. Rotation of cells in an alternating electric field: theory and experimental proof. J. Membr. Biol. 67: 13-26.
22. Fuhr, G., R. Glaser & R. Hagedorn. 1986. Rotation of dielectrics in a rotating electric high-frequency field. Model experiments and theoretical explanation of the rotation effect of living cells. Biophys. J. 49: 395-402.
23. Fuhr, G., T. Muller & R. Hagedorn. 1989. Reversible and irreversible rotating field-induced membrane modifications. Biochem. Biophys. Acta 980: 1-8.
24. Maier, H. 1997. Electrorotation of colloidal particles and cells depends on surface charge. Biophys. J. 73: 1617-1626.
25. Goater, A.D. & R. Pethig. 1998. Electrorotation and dielectrophoresis. Parasitology 117: S177-S189.
26. Lee, S.X. et al. 2011. CB-17. Mitosis interference of cancer cells during anaphase by electric field from NovoTTF-100A. In Society for Neuro Oncology Annual Meeting, Orange County, California. Vol. 13: pp. iii1-iii9.
27. Kirson, E.D. et al. 2007. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc. Natl. Acad. Sci. USA 104: 10152-10157.
28. Pless, M. & U. Weinberg. 2011. Tumor treating fields: concept, evidence and future. Exp. Opin. Invest. Drugs 20: 1099-1106.
29. Schneiderman, R. et al. 2008. Synergism between chemotherapy and alternating electric fields (TTFields) in cancer cell proliferation inhibition and solid tumor treatment. AACR Meeting Abstr. 2008: 1007.
30. Rulseh, A.M. et al. 2012. Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields. World J. Surg. Oncol. 10: 220.
31. Hanna, N. et al. 2004. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J. Clin. Oncol. 22: 1589-1597.
32. National Cancer Institute 2012. Adult Brain Tumors Treatment PDQ, Vol. 2012. NCI.
33. Huse, J.T., E. Holland & L.M. Deangelis. 2012. Glioblastoma: molecular analysis and clinical implications. Annu. Rev. Med.
34. Ohka, F., A. Natsume & T. Wakabayashi. 2012. Current trends in targeted therapies for glioblastoma multiforme. Neurol. Res. Intern 2012: 1-13.
35. Iwamoto, F.M. et al. 2009. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73: 1200-1206.
36. Stupp, R. et al. 2010. A prospective, randomized, open-label, phase III clinical trial of NovoTTF-100A versus best standard of care chemotherapy in patients with recurrent glioblastoma. J. Clin. Oncol. 28: LBA2007.
37. Ram, Z., P.H. Gutin & R. Stupp. 2010. Subgroup and quality of life analyses of the phase iii clinical trial of NovoTTF-100A versus best standard chemotherapy for recurrent glioblastoma. Neuro Oncol. 12(Suppl. 4).
38. Ram, Z. 2011. Comparing the effect of NovoTTF to bevacizumab in recurrent GBM: a post-hoc sub-analysis of the phase III trial data. Neuro Oncol. 13(Suppl. 3).
39. Hendrick, B. 2011. FDA Approves New Device for Brain Tumor Treatment. New York: WebMD.
40. NCCN. 2013. NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers.
41. Gutin, P.H. & E.T. Wong. 2012. "Noninvasive application of alternating electric fields in glioblastoma: a fourth cancer treatment modality." In ASCO 2012 Educational Book. VA: American Society of Clinical Oncology.